Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) EBIT (2022 - 2025)

Historic EBIT for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to -$3.6 million.

  • Atara Biotherapeutics' EBIT rose 8357.31% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.2 million, marking a year-over-year increase of 11998.67%. This contributed to the annual value of -$83.4 million for FY2024, which is 6976.95% up from last year.
  • Atara Biotherapeutics' EBIT amounted to -$3.6 million in Q3 2025, which was up 8357.31% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, Atara Biotherapeutics' EBIT registered a high of $38.8 million during Q1 2025, and its lowest value of -$88.2 million during Q1 2022.
  • Its 4-year average for EBIT is -$40.1 million, with a median of -$32.1 million in 2022.
  • As far as peak fluctuations go, Atara Biotherapeutics' EBIT plummeted by 12225.2% in 2023, and later surged by 22417.83% in 2025.
  • Quarter analysis of 4 years shows Atara Biotherapeutics' EBIT stood at -$75.5 million in 2022, then rose by 20.62% to -$60.0 million in 2023, then surged by 79.65% to -$12.2 million in 2024, then soared by 70.71% to -$3.6 million in 2025.
  • Its last three reported values are -$3.6 million in Q3 2025, $3.2 million for Q2 2025, and $38.8 million during Q1 2025.